Leap Therapeutics faces a precarious outlook as its reliance on high-cost clinical development continues to erode its capital base without a corresponding commercial revenue stream.
Price trend, volume and key moving averages
Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Benchmark LPTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Leap Therapeutics, Inc. (LPTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.77 | $64.53M | 10.99 | — | — | 5.11% | — | |
| $30.53 | $6.3B | -11.02 | — | -7585.86% | -69.59% | — | |
| $7.15 | $297.74M | -2102.94 | 10.37% | 69.76% | — | — | |
| $59.83 | $9.16B | 21.60 | 87.32% | 55.22% | 72.3% | — | |
| $18.28 | $2.3B | -5.56 | -4.26% | -386.32% | -87.98% | — | |
| $37.26 | $1.23B | -3.83 | -43.89% | -287.84% | -37.99% | — |
Leap Therapeutics, Inc. (LPTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Leap Therapeutics, Inc. (LPTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 26, 2026·SEC
May 14, 2026·SEC
Apr 10, 2026·SEC
Get notified when LPTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Leap Therapeutics, Inc. (LPTX) stock FAQ — growth, dividends, profitability & financials explained
Leap Therapeutics, Inc. (LPTX) reported $0.2M in revenue over the trailing twelve months.
No. Leap Therapeutics, Inc. (LPTX) reported a net loss of $56.9M over the trailing twelve months.
Leap Therapeutics, Inc. (LPTX) had a return on equity (ROE) of 5.1% in fiscal year 2025. That is below the market's typical 10-15%.
Leap Therapeutics, Inc. (LPTX) had negative free cash flow of $79.6M over the trailing twelve months.
